Objective: To evaluate the accuracy of repeat mediastinoscopy (reMS) in all its indications, and to analyse survival in the group of patients who underwent induction chemotherapy or chemoradiotherapy for pathologically proven stage III-N2 non-small-cell lung cancer (NSCLC). Methods: From July 1992 to February 2009, 96 patients (87 men; median age: 61.3 years), underwent 101 reMSs (five patients required a second reMS) for the following indications: restaging after induction therapy for pathologically proven N2 disease (84 cases), inadequate first mediastinoscopy (five), metachronous second primary (six) and recurrent lung cancer (six). Patients with N2-NSCLC, who had received induction therapy and had positive reMS, underwent definitive chemotherapy or chemoradiotherapy. Patients in whom reMS was negative underwent thoracotomy for lung resection and systematic nodal dissection (SND). SND was considered the gold standard to compare the negative results of reMS. Pathologic findings were reviewed and staging values were calculated using the standard formulas. Follow-up data were completed in January 2010, and survival analysis was performed by the Kaplan-Meier method. Results: In the group of reMS for restaging after induction therapy, the staging values were: sensitivity 0.74, specificity 1, positive predictive value 1, negative predictive value 0.79 and diagnostic accuracy 0.87. We also determined the diagnostic value of this technique according to the type of induction treatment. In terms of accuracy, no statistically significant differences were found. Median survival time in patients with true negative reMS was 51.5 months (95% confidence interval (CI) 0-112), and in the combined group of patients with positive and false-negative reMS, median survival time was 11 months (95% CI 7.6-14.1) ( p = 0.0001). In the group of miscellaneous indications, all staging values were 1. Conclusion: ReMS is feasible in all the indications described. After induction therapy, it is a useful procedure to select patients for lung resection with high accuracy, independently of the induction treatment used or the intensity of the first mediastinoscopy. The persistence of lymph node involvement after induction therapy has a poor prognosis. Therefore, techniques providing cytohistological evidence of nodal downstaging are advisable to avoid unnecessary thoracotomies. #
Introduction
The results of recent randomised clinical trials on multimodality treatment for pathologically proven N2 nonsmall-cell lung cancer (NSCLC) have shown that the persistence of mediastinal nodal disease after induction treatment is associated with poor prognosis, and that the best postoperative survival is associated with mediastinal nodal dowstaging [1, 2] . Whether this improved survival is the result of lung resection or of the induction therapy is unknown. Until we have evidence from properly designed clinical trials comparing surgical resection with other therapeutic modalities or no further treatment for patients with pathologically proven mediastinal nodal downstaging after induction treatment, it does not seem justified to operate on all patients after induction therapy. Restaging to assess objective tumour response after induction can be performed in many different ways. Imaging techniques have low sensitivity [3] [4] [5] [6] and ultrasound-guided endoscopies with fine needle aspiration are not universally available and have a low negative predictive value [7] [8] [9] [10] [11] . Repeat mediastinoscopy (reMS) provides pathological evidence of response after induction therapy. Although the main purpose of reMS is restaging after induction therapy, this procedure can be performed for other indications: assessment of second primary or recurrent tumours; in patients in whom the first mediastinoscopy (MS) was incomplete; in patients with a delayed commencement of treatment; and in those cases with lung cancer occurring after unrelated disease (such as lymphoma, sarcoidosis or other granulomatous disease) [4, 12] . ReMS is technically more demanding because of peritracheal adhesions, resulting in a lower accuracy compared with a first procedure; because of this, most thoracic surgeons consider this technique hazardous and unsafe, especially when induction therapy includes radiotherapy.
The objective of this report is to describe our experience over the last two decades on reMS in all its indications, especially in restaging after induction therapy.
Materials and methods
From July 1992 to February 2009, 96 patients (87 men; median age: 61.3 years, range 21-79 years), underwent 101 reMSs (five patients required a repeat reMS) for the following indications: restaging after induction therapy for pathologically proven N2 disease (84 cases), inadequate first MS (five: in four, the indication was for suspected lymphoma), metachronous second primary (six) and recurrent lung cancer (six).
Preoperative work-up of patients with NSCLC
Between 1992 and 2003, our staging protocol included bronchoscopy, computed tomography (CT) of the chest and upper abdomen and bone scan; CT of the brain was reserved for symptomatic patients or for those with locally advanced tumours. Operability was assessed by medical history and physical examination, electrocardiograph (EKG), pulmonary function tests and ventilation-perfusion lung scans in patients with forced expiratory volume in 1 s (FEV1) of 2000 ml or less and tumours requiring pneumonectomy or with FEV1 of 1500 ml or less and tumours requiring lobectomy. Surgical exploration of the mediastinum (MS for tumours of the right lung and MS with left parasternal mediastinotomy or extended cervical mediastinoscopy for tumours of the left lung) was performed routinely, that is, regardless of the size of the nodes on CT scan, as the final staging procedure before thoracotomy, once distant metastases had been ruled out, the tumour had been deemed resectable and operability had been established. Following this protocol, 55 cases of this series underwent routine surgical exploration of the mediastinum. In 2004, routine positron emission tomography (PET) or PET-CT scan was introduced in the staging protocol, and bone scan was not performed routinely any more. There were no changes in the assessment of operability. With this new protocol, surgical exploration of the mediastinum was indicated when there was mediastinal uptake on PET scan and in the following situations when PET scan did not show any suspicious uptake in the mediastinum: hilar uptake, central tumours, tumours contacting the mediastinum and when there were enlarged lymph nodes (over 1 cm in the short axis) on the CT scan. The criteria for contraindication to curative resection resulting from the mediastinal exploration were ipsilateral and contralateral mediastinal nodal disease, direct tumour invasion of mediastinal structures and a diagnosis of small cell carcinoma. Moreover, extracapsular lymph node involvement was considered a criterion for incomplete resection.
Induction therapy
Until 1993, patients who were not eligible for operation on the basis of the above-mentioned criteria received radiotherapy on the tumour and mediastinum as the only definitive therapeutic option. In January 1994, an induction chemotherapy protocol for pathologically proven N2 disease on the basis of preceding experiences was started [13, 14] . Those patients with N2/N3 NSCLC diagnosed at MS, and with a Karnofsky index 70% or over, received induction cisplatinumbased chemotherapy (49 cases) or chemoradiotherapy (35 cases). Regarding radiotherapy, 45 Gy were given to the primary tumour and involved mediastinal nodes.
Restaging after induction therapy
At completion of induction therapy, restaging was performed by means of posteroanterior and lateral chest roentgenograms, fibreoptic bronchoscopy and CTof the chest and upper abdomen. Other diagnostic aids, such as CT of the brain or bone scan, were performed selectively upon clinical indication, if extrathoracic extension was suspected during induction therapy. In 2004, routine PET or PET-CT scan was introduced in this restaging protocol to evaluate the metabolic response in the mediastinum and to rule out extrathoracic disease. Those patients who, according to radiologic and metabolic criteria, showed no progressive disease underwent reMS to evaluate the response to induction therapy and rule out persistent mediastinal involvement. In fact, reMS intended to select those patients who could undergo complete resection.
ReMS was generally performed by the same surgeon, who had performed the first exploration, approximately 1 month after completion of induction therapy. The technique does not differ much from MS. The procedure is started by resecting the scar of the previous incision. Once the platysma and the subcutaneous tissue are incised and the pretracheal muscles are separated laterally, the pretracheal fascia is reopened. This is not as easy as in the initial MS, because it is thicker. Pretracheal adhesions, caused by the previous procedure, are invariably found. Peritracheal digital dissection allows the creation of enough peritracheal room to insert the mediastinoscope. These adhesions rarely bleed. Generally, the mediastinoscope is more easily inserted obliquely through the left paratracheal space, as there usually are less lymph nodes at this site, having been less manipulated than the right side at the time of the first MS. From this position, the remaining adhesions can be freed with digital dissection or with the dissection-coagulation-suction cannula or bipolar endoscopic scissors. Next, those nodes that had been positive at the staging MS are biopsied. If it is technically feasible, other nodal stations are also reached to rule out sub-clinical progression of the disease. All biopsy samples taken during the exploration are sent for intra-operative pathologic examination, and the operation is terminated once an involved node is found.
Those patients with residual N2 or N3 disease underwent definitive chemotherapy or chemoradiotherapy. In the absence of nodal disease at reMS, a posterolateral thoracotomy for lung resection and systematic nodal dissection (SND) was performed.
At the beginning of this series, reMS and thoracotomy were scheduled together on the same day [4] . However, occasional discrepancies between frozen section and definitive pathologic results were recognised. For this reason, after the first 24 patients, thoracotomy was scheduled 10-15 days after reMS, and its indication based on the definitive pathology report. At thoracotomy, SND with frozen sections examination of all nodes is performed before lung resection, especially in those patients requiring a pneumonectomy.
Definitions, statistics and survival analysis
The intensity of the first MS depends on the number of lymph node stations explored and lymph nodes biopsied. Complete first MS was defined as an exploration that included biopsy specimens of at least one ipsilateral, one contralateral and one subcarinal lymph node, following the recommendations of the European Society of Thoracic Surgeons (ESTS) guidelines for preoperative lymph node staging for NSCLC [15] .
Sensitivity, specificity, positive and negative predictive values and diagnostic accuracy of reMS were calculated using the standard formulas. These staging values were calculated according to the type of induction treatment and according to the intensity of the first MS. Fisher's exact test was used for group comparison when appropriate.
SND was considered the gold standard to compare the negative results. In the group of reMS for restaging after induction therapy, one patient was excluded from this analysis, because thoracotomy was not performed due to acute myocardial infarction.
Follow-up data were completed in January 2010; the latest reMS in this series was performed in February 2009. Hence, the minimum follow-up for surviving patients was 11 months. Survival analysis was performed by the KaplanMeier method. Postoperative death, defined as that occurring within 30 days after thoracotomy, was excluded from the survival analysis. A p value of less than 0.05 was considered significant.
Results
ReMS was technically feasible in all patients. The complication rate was 4% with one superficial wound infection, treated with drainage and antibiotics; one unintended biopsy of the right lung with no further consequences; one bronchial injury of the right main bronchus treated with sealant patch; and a puncture of the superior vena cava with the coagulation device that required packing and right thoracotomy, during which a right pneumonectomy was performed. One patient died due to haemorrhage from the origin of the innominate artery, causing tamponade and cardiac arrest.
In the group of miscellaneous indications (17 cases), reMS was positive in six cases and negative in 11 cases. In two patients, a negative reMS was considered true negative by follow-up: suspected lymphoma, which was not confirmed after 20 months, and a benign paratracheal cyst (36 months).
The staging values of these reMS for other indications (sensitivity, specificity, negative predictive value, positive predictive value and accuracy) were 1.
In the group of reMS for restaging after induction therapy (84 cases), reMS was positive in 31 cases and negative in 52 (one patient with negative reMS was excluded from analysis because thoracotomy was not performed). There were 11 false-negative reMSs, giving the following global staging values: sensitivity 0.74, specificity 1, positive predictive value 1, negative predictive value 0.79 and diagnostic accuracy 0.87. In the false-negative group, persistent mediastinal nodal disease was found after definitive pathological examination in the following lymph node stations: subcarinal (five cases), right inferior paratracheal (five cases) and subaortic (1 case). The diagnostic value of reMS according to the type of induction treatment and the intensity of the first MS was also determined. For each comparison (reMS after chemotherapy vs chemoradiotherapy, and reMS after complete first MS vs incomplete first MS) no statistically significant differences were found (Tables 1  and 2 ).
Follow-up was complete in all patients with reMS for restaging after induction therapy (84 reMS in 81 patients, but one patient was excluded from this group, because thoracotomy was not performed due to acute myocardial infarction). Regarding the postoperative period, 11 (13.5%) patients died. In this subgroup, the following lung resections were performed: five lobectomies (one right upper lobectomy with en bloc chest wall resection and one right upper sleeve lobectomy), two bilobectomies and four right pneumonectomies. The causes of death were: sepsis (three patients), adult respiratory distress syndrome (three patients) and massive haemoptysis (two patients). The three remaining patients died at home of unknown cause.
Regarding the follow-up of the rest of this series, 50 patients died, mostly of distant metastases.
The median survival time in patients with true negative reMS was 51.5 months (95% confidence interval (CI) 0-112), and in the combined group of patients with positive and falsenegative reMS, the median survival time was 11 months (95% CI 7.6-14.1). The difference between these two groups was significant ( p = 0.0001). Analysing the latter two groups individually, the median survival time was: 12 months (95% CI 6.8-17.3) in those patients with a positive reMS, and 7 months (95% CI 4.7-9.3) in those patients with a falsenegative reMS (Table 3 and Figs. 1 and 2) . The difference between these groups was significant ( p = 0.0001).
Discussion
The prognosis of loco-regionally advanced lung cancer is overall poor, with 5-year survival rates ranging from 5% to 15%. With the introduction of multimodal treatment, including induction chemotherapy or chemoradiotherapy and surgical intervention, an improvement of the expected survival has been observed [16] [17] [18] .
In multimodality approaches, an accurate evaluation of objective response after induction therapy continues to represent a diagnostic challenge to define which patients will benefit from surgical treatment. In two recent phase III clinical trials conducted in Europe [1] and in North America [2] , it has been shown that those patients with persisting mediastinal involvement do not benefit from surgical resection in terms of survival. Thus, surgical intervention should be reserved exclusively for those selected patients with pathologic evidence of complete response in the mediastinum after the induction treatment.
All the methods available for staging can be used for restaging, but those that do not provide us with cytohistological evidence are unreliable. Standard staging procedures, such as CT and magnetic resonance imaging (MRI), are of limited value in the evaluation of objective response after induction therapy because of their intrinsic inability to differentiate between viable tumour and necrosis or scarring on a morphologic basis, thus resulting in low accuracy to stage either the primary tumour or mediastinal lymph nodes [ ( ) T D $ F I G ] Fig. 1 . Survival curve after reMS showing true negative, positive and falsenegative subgroups. [3, 5] . In our initial experience with reMS published in 2000 [4] , the value of CT in mediastinal restaging was also analysed, and showed that the presence or absence of lymph nodes depending on radiological size (more than 1 cm in greatest diameter) was of little value and misleading: 40% of patients with enlarged lymph nodes had no tumour nodal involvement. PET or PET/CT provides additional metabolic information, and is more accurate in predicting the T (tumour) component than the N (node) status compared with CT. However, its restaging value is low: sensitivity ranges between 0.50 and 0.77; negative predictive value, between 0.64 and 0.85; and diagnostic accuracy, between 0.70 and 0.83 [5, 6] .
Several other minimally invasive techniques for restaging the mediastinum provide cytological proof of mediastinal involvement. These include oesophageal ultrasonography (EUS) with fine-needle aspiration (FNA) and endobronchial ultrasonography (EBUS) with FNA. Although there is little experience with these new explorations in restaging after induction therapy, the reported restaging values are improving with an accuracy similar to that of reMS [7] [8] [9] [10] [11] . However, these techniques are costly and are not available everywhere. The recent ESTS guidelines for preoperative lymph node restaging for NSCLC, either based initially on CT or PET/PET-CT, recommend histological confirmation of objective response after induction therapy. This confirmation can be done with surgical interventions -reMS in our experience -or, if available, with ultrasound-guided endoscopic techniques. However, confirmation with an invasive surgical technique is still recommended when the results of endoscopic procedures are negative [15] . Table 4 shows the results of reMS published to date and those of the present series. In all series [6, [19] [20] [21] , the sensitivity of reMS is over 0.60 (range, 0.60-0.74) with an accuracy greater than 0.80 (range, 0.80-0.92), except for the prospective series reported by de Leyn et al. [6] In this study, integrated PET/CTwas compared with reMS in 30 patients. The sensitivity of reMS was only 0.29 with an accuracy of 0.60. This low sensitivity is largely explained by the fact that biopsy of the subcarinal nodes was not adequately performed in 20 patients (67%). The authors suggested that a complete reMS is not possible after a thorough MS [22] .
Although reMS is somewhat more complex than initial MS due to the presence of peritracheal adhesions, this study has shown its high diagnostic value independently of the induction treatment used (chemo-or chemoradiotherapy) and the intensity of the first MS (Tables 1 and 2 ).
There are few reports specifically studying survival after reMS [19, 21, 23, 25] . Stamatis et al. reported a 5-year survival rate of 5% for patients with persisting N2 disease. De Waele et al. combined the results of 46 reMS performed at the Hospital of Antwerp and 58 reMS of the present series performed at Hospital Universitari Mutua Terrassa. They reported a median survival time of 41 and 7 months for negative and positive reMS, respectively ( p = 0.003). Our previously reported results showed a 5-year survival rate for patients with downstaged nodal disease (ypN0) (n = 12) of 20% in contrast to 0% for patients with positive reMS (ycN2) or false-negative reMS (ypN2) (n = 24). This difference was not significant, probably due to the few number of patients with long-term follow-up [24] . In the present series with a followup ranging from 11 to 128 months for surviving patients, the difference between positive and negative reMS was highly significant ( p = 0.0001), with a median survival time of 51.5 months in patients with true negative reMS, and 11 months in the group of patients with positive and false-negative reMS. These results show the poor prognosis of those patients with persistent mediastinal disease, and the poor benefit of surgical resection in the group of patients with falsenegative reMS.
Regarding the use of reMS for other indications, there are few authors reporting their experience. Recently, De Waele et al. described their overall experience with 79 reMSs, emphasising its high accuracy and feasibility in the group of other indications (25 cases) [25] . Our findings are in accordance with the results of De Waele et al., and also confirm the reliability of reMS in other indications.
Published series on reMS [6, [19] [20] [21] describe few complications with a morbidity rate ranging from 0% to 4%. The complications of this present study fall within the range of Table 4 . Staging values of published series of reMS for restaging after induction therapy and our study.
Stamatis et al. [19] (N = 160)
De Leyn et al. [6] (N = 30) Marra et al. [20] (N = 104)
De Waele et al. [21] (N = 104) the published results. Regarding mortality, only one death has been reported. However, as described elsewhere [23] , this death was not related to improper surgical technique but to a suboptimal indication of multimodality treatment in a very marginal patient with generalised atheromatous disease, who should have never been included in a multimodality therapy protocol.
In conclusion, reMS is feasible in all the indications described. In its main indication, restaging after induction therapy, it is a useful procedure to select patients for lung resection with high accuracy, independently of the induction treatment used (chemotherapy alone or chemoradiation) or the intensity of the first MS. Persistent mediastinal lymph node involvement after induction therapy is associated with poor prognosis, and lung resection in this group of patients does not add any survival benefit. Therefore, techniques providing cytohistological information are advisable to avoid thoracotomies with no therapeutic value.
